Studies reporting on PD-1/PD-L1–targeting therapy in metastatic colorectal cancer in the context of sites of metastases have been limited by their small sample sizes and lack of multivariate analysis that integrates sidedness, results of molecular analysis, and TMB. This evidence concerns the gene CD274 and metastatic colorectal cancer.